How can we help your research?
Pharma & Biotech
De-risk drug development and validate your pipeline with human ex vivo skin data. Replace animal models with clinically relevant human tissue.
Cosmetics & Beauty
Substantiate safety, efficacy, and product claims with human skin data that regulators and consumers trust. Replace in vitro with real tissue.
Medical Devices
Assess biocompatibility and local skin tolerance with human tissue reflecting real-world response. Meet regulatory requirements with confidence.
Academic Research
Access well-characterized ex vivo skin models and expert services for discovery, validation, and publication-ready human tissue data.
Expert-designed studies and research-ready products for every need
Predict Injection Site Reactions before clinical trials
HypoSkin® enables human-relevant injection site reaction (ISR) testing for injectable therapeutics using ex vivo human skin. This NAM-based platform evaluates local immune activation and tissue response to support safer, better-informed development decisions.
Controlled intradermal injection. Administration into ex vivo human skin in a multi-well plate for injection site reaction analysis.
Human-relevant local tolerance assessment
HypoSkin® evaluates local tolerance and cytotoxicity following administration of vaccines, therapeutics, and medical devices. With native immune cells in real human skin, it delivers actionable, human-relevant insight, advancing New Approach Methodologies that reduce reliance on animal testing.
Local tolerance at D5. Water vs. a commercially available compound injected at D0; H&E staining reveals epidermal separation at the epidermal–dermal junction.
Human-relevant models for inflammatory skin disease research
InflammaSkin® and our Atopic Dermatitis platform replicate the immune and barrier-dysfunction mechanisms underlying psoriasis and atopic dermatitis. Native human skin with preserved architecture and immune populations enables early, confident evaluation of therapeutic efficacy.
Disease-relevant marker expression. InflammaSkin® assessed by H&E and K16 immunostaining (DAPI counterstaining).
Topical and transdermal testing on live, immunocompetent human skin
NativeSkin® generates robust, human-relevant efficacy and safety data for compounds, ingredients, formulations, and finished products. Viable for up to 10 days in culture, it supports absorption, barrier function, irritation, UV exposure, cytokine profiling, biomarker expression, and histology.
Skin integrity after UV exposure. Day 2 and Day 7 after a single Day 1 exposure (25 J/cm² UVA + 30 mJ/cm² UVB) vs. non-exposed PBS controls.
Order ready-to-use human skin models and mast cells
Order ex vivo human skin models and primary human mast cells directly through our e-shop, with global shipping, handling instructions, and scientific support included. Ready-to-use products deliver human-relevant data fast, with viable tissue arriving at your lab in a few business days.
Don’t see your industry or study type? Tell us about your research →
Ex vivo human skin vs. reconstructed skin vs. animal models
The most predictive non-clinical model depends on what you’re testing. Here’s how Genoskin’s ex vivo human skin compares.
| Feature | Genoskin — Ex vivo human skin | Reconstructed Skin | Animal Models |
|---|---|---|---|
| All native cell types | ✓Full immune compartment | ✗Keratinocytes only, no immune cells | ✗0 human immune cells, cross-species gap |
| Human-relevant data | ✓Direct clinical translation | ~Partial | ✗Non-human biology, poor translation |
| Full skin layers | ✓Epidermis + dermis + hypodermis | ✗Epidermis only | ~All layers, but anatomically different |
| Skin appendages | ✓Hair follicles, sweat glands preserved | ✗None | ~Different structure |
| Immune response profiling | ✓Spatial biology + multiomics | ✗No immune cells | ✗Reduced translational relevance |
| Ethical sourcing | ✓Consented human donation | ~Human-derived cells, varying consent rigor | ✗Animal use required |
| NAMs regulatory direction | ✓Aligned with FDA & EMA frameworks | ~Limited context of use | ~Reduced regulatory preference post-FDA Modernization Act 2.0 |
The benchmark in human skin science
75%
Of top pharma companiesHave run studies with us
10 days
Viable & immunocompetentIn culture
90+
Peer-reviewed publications2/3 by our customers
500+
Customers worldwideAcross all industries
ISO 9001:2015 quality management certified
Genoskin’s main facility in France has been certified since 2017, ensuring consistently high-quality products & services
Two ways to work with us
Custom CRO services or self-serve skin models. Both backed by the same science.
Frequently asked questions
How does ex vivo human skin differ from reconstructed skin models, and why does it matter?
Is ex vivo human skin accepted for IND submissions under the FDA Modernization Act 2.0?
How reproducible are Genoskin's results given that models come from different human donors?
How long is ex vivo human skin viable, and what's the typical turnaround time for a Genoskin study?
Genoskin’s patented biostabilization technology keeps ex vivo human skin alive and immunocompetent for up to 10 days in culture, which is sufficient for the vast majority of safety, tolerability, and multi-timepoint dose-response studies. For custom CRO studies, most projects kick off within 2 weeks of contract signature and are completed within 4 to 8 weeks from initiation to final report. E-shop orders ship globally and arrive viable at your lab to start your experiments.
Where do you ship, and is the skin ethically sourced?
Have more questions? Visit our FAQ page →
From donated skin to reliable human data
Step 1
Ethically sourced
Human skin from consented surgical donations, processed within hours. Every sample is ethically sourced and fully traceable.
Step 2
Biostabilized
Our patented technology keeps tissue alive and immunocompetent for up to 10 days in culture, with 14 immune cell types naturally preserved.
Step 3
Human-relevant data
Translational endpoints: histology, multiplex cytokine analysis, spatial biology, flow cytometry, and bioinformatics.
“
“What is needed in order to reduce the failure rate of novel drugs in clinical development are techniques that provide a better insight in PK and PD processes in clinical trials such as the dOFM and the use of human tissue as provided by Genoskin.”
Florian P. et al.
“
“This study underscores the power of combining new approach methodologies, like our viable human skin model, with innovative biologics. The results provide a strong foundation for continued clinical advancement of MTX-001.”
Dr. Aaron Strickland
“
“The results confirm and build upon previous reported results from ex-vivo studies done with human skin specimens conducted by Genoskin, as well as in a plaque psoriasis in vitro model using human skin tissue grown in a dish.”
Scinai Immunotherapeutics Ltd.
(Nasdaq: SCNI)
About Genoskin
Human Skin. Real answers.
Founded in Toulouse in 2011 by Dr. Pascal Descargues (PhD, CNRS), Genoskin pioneered the world’s first biostabilized ex vivo human skin platform, a breakthrough that finally bridges the gap between lab models and clinical reality. We’ve since expanded our technology with HypoSkin®, the only injectable ex vivo model incorporating the hypodermis, and have rigorously characterized immunocompetency across both platforms.
Today, from our labs in Toulouse and Salem, MA, we partner with 500+ customers across pharma, biotech, vaccines, cosmetics, and academic research, helping them make better decisions, faster, with human skin that behaves like human skin.
Fresh from the lab: webinars, insights, and publications, updated regularly.
Featured in 90+ peer-reviewed publications
